Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA.

Science. 1996 May 24;272(5265):1167-70. Erratum in: Science 1997 Jan 3;275(5296):14.

PMID:
8638160
2.

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr.

Ann Intern Med. 1997 Jun 15;126(12):946-54.

PMID:
9182471
3.

Viral counts count in HIV infection.

Ho DD.

Science. 1996 May 24;272(5265):1124-5. Review. No abstract available.

PMID:
8638155
4.

CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.

Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):332-40.

PMID:
9704938
5.

[The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].

Rubio Caballero M, Nogués Biau A, Falguera Sacrest M, Puig Ganau T, Lecha N, Rubio Rivas C.

An Med Interna. 2000 Oct;17(10):533-7. Spanish.

PMID:
11109648
6.

Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children.

Rouet F, Sakarovitch C, Msellati P, Elenga N, Montcho C, Viho I, Blanche S, Rouzioux C, Dabis F, Leroy V; Abidjan ANRS 049 Ditrame Study Group.

Pediatrics. 2003 Oct;112(4):e289.

PMID:
14523214
7.

Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.

Blattner WA, Oursler KA, Cleghorn F, Charurat M, Sill A, Bartholomew C, Jack N, O'Brien T, Edwards J, Tomaras G, Weinhold K, Greenberg M.

J Infect Dis. 2004 May 15;189(10):1793-801. Epub 2004 Apr 26.

8.

Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.

Messele T, Brouwer M, Girma M, Fontanet AL, Miedema F, Hamann D, Rinke de Wit TF.

Clin Immunol. 2001 Feb;98(2):212-9.

PMID:
11161977
9.

Calculation and use of an HIV-1 disease progression score.

Roussanov BV, Taylor JM, Giorgi JV.

AIDS. 2000 Dec 1;14(17):2715-22.

PMID:
11125890
10.

Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients.

Valentine ME, Jackson CR, Vavro C, Wilfert CM, McClernon D, St Clair M, Katz SL, McKinney RE Jr.

Pediatr Infect Dis J. 1998 Jan;17(1):18-23.

PMID:
9469389
11.

Effect of persistent moderate viremia on disease progression during HIV therapy.

Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D'Aquila R, Mangialardi WJ, Fusco GP; Collaborations in HIV Outcomes Research/United States Project.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1147-54.

PMID:
15319674
12.

Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.

Matheron S, Pueyo S, Damond F, Simon F, Leprêtre A, Campa P, Salamon R, Chêne G, Brun-Vezinet F; French HIV-2 Cohort Study Group.

AIDS. 2003 Dec 5;17(18):2593-601.

PMID:
14685053
13.

AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion.

de Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, Bakker M, Roos M, Coutinho R, Miedema F, Goudsmit J.

AIDS. 1997 Dec;11(15):1799-806.

PMID:
9412697
14.

Early and late HIV-1 RNA level and its association with other markers and disease progression in long-term AIDS-free homosexual men.

Spijkerman IJ, Prins M, Goudsmit J, Veugelers PJ, Coutinho RA, Miedema F, de Wolf F.

AIDS. 1997 Sep;11(11):1383-8.

PMID:
9302449
15.

Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells.

Stellbrink HJ, van Lunzen J, Hufert FT, Fröschle G, Wolf-Vorbeck G, Zöllner B, Albrecht H, Greten H, Racz P, Tenner-Racz K.

AIDS. 1997 Jul 15;11(9):1103-10.

PMID:
9233456
16.

Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline.

Iuliano R, Forastieri G, Brizzi M, Mecocci L, Mazzotta F, Ceccherini-Nelli L.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):408-14.

PMID:
9170414
17.

The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection.

Lefrère JJ, Roudot-Thoraval F, Mariotti M, Thauvin M, Lerable J, Salpétrier J, Morand-Joubert L.

J Infect Dis. 1998 Jun;177(6):1541-8.

18.

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.

Sterling TR, Chaisson RE, Moore RD.

AIDS. 2001 Nov 23;15(17):2251-7.

PMID:
11698698
20.

Viral dynamics in human immunodeficiency virus type 1 infection.

Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al.

Nature. 1995 Jan 12;373(6510):117-22.

PMID:
7529365
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk